Cytokinetics, Incorporated beat EPS estimates 31% of the time across 16 reported quarters (5 beats, 11 misses), averaging -12.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-1.63 | $-1.50 | +8.0% | Beat | |
| Q1 FY26 | $-1.67 | $-1.67 | +0.0% | Beat | |
| Q4 FY25 | $-1.48 | $-1.50 | -1.4% | Miss | Q4 FY25 call |
| Q3 FY25 | $-1.59 | $-1.54 | +3.1% | Beat | |
| Q2 FY25 | $-1.34 | $-1.12 | +16.4% | Beat | |
| Q1 FY25 | $-1.41 | $-1.36 | +3.5% | Beat | |
| Q4 FY24 | $-1.22 | $-1.26 | -3.3% | Miss | |
| Q3 FY24 | $-1.27 | $-1.36 | -7.1% | Miss | |
| Q2 FY24 | $-1.02 | $-1.31 | -28.4% | Miss | |
| Q1 FY24 | $-1.16 | $-1.33 | -14.7% | Miss | |
| Q4 FY23 | $-1.03 | $-1.38 | -34.0% | Miss | |
| Q3 FY23 | $-0.72 | $-1.35 | -87.5% | Miss |
Back to CYTK overview · CYTK holders · CYTK KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.